文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

撒哈拉以南非洲脓毒症转录组内型的识别:两个乌干达队列的推导、验证与全球比对

Identification of transcriptomic sepsis endotypes in sub-Saharan Africa: derivation, validation, and global alignment in two Ugandan cohorts.
PubMed 文献 · Intensive Care Med · 2025-07-29
一句话结论乌干达脓毒症患者中识别出两种转录组内型,USE-2以中性粒细胞驱动固有免疫激活和淋巴细胞抑制为特征,与更高的生理严重度和死亡率相关(41.3% vs 22.0%)。

该研究基于乌干达两个前瞻性观察队列(发现队列Tororo农村N=243,验证队列Entebbe城市N=112)的危重成人脓毒症患者,对全血RNAseq数据进行无监督聚类,在发现队列中识别出USE-1和USE-2两种内型,并用随机森林分类器在验证队列中预测内型分配。USE-2以中性粒细胞驱动的固有免疫激活和淋巴细胞抑制为标志,与更高的生理严重度和死亡率相关(41.3% vs 22.0%;绝对差19.3%,95%CI 7.6-30.9%),且不受HIV、结核或疟疾感染影响。13基因分类器(误分类率1.43%)在验证队列中复制出两种内型,生物学和临床特征相似。USE-2与SRS1和炎症型内型有强转录重叠,但患者层面分配仅中度一致;与Mars1的重叠可变。作者结论认为,这些内型反映了可靶向病理生物学的个体间差异,并在高负担感染中提供预后富集,与高收入国家内型的差异凸显了需要兼具全球相关性和本地响应性的脓毒症分类。

要点

  • 在乌干达脓毒症危重成人中识别出两种转录组内型USE-1和USE-2,USE-2与更高死亡率相关(41.3% vs 22.0%;绝对差19.3%,95%CI 7.6-30.9%)。
  • USE-2以中性粒细胞驱动的固有免疫激活和淋巴细胞抑制为特征,与更高生理严重度相关,且不受HIV、结核或疟疾感染影响。
  • 13基因分类器(误分类率1.43%)在独立验证队列中复制出两种内型,生物学和临床特征相似。
  • USE-2与高收入国家来源的SRS1和炎症型内型有强转录重叠,但患者层面分配仅中度一致;与Mars1重叠可变。
  • 作者结论认为这些内型反映可靶向病理生物学的个体间差异并在高负担感染中提供预后富集,与高收入国家内型的差异提示需发展兼具全球相关性和本地响应性的脓毒症分类。

适用人群与场景

  • 乌干达两个前瞻性观察队列的危重成人脓毒症患者:发现队列位于Tororo农村(N=243),验证队列位于Entebbe城市(N=112)。

研究设计与关键结果

  • 研究设计:两个前瞻性观察队列(发现队列Tororo农村N=243,验证队列Entebbe城市N=112),对全血RNAseq数据行无监督聚类识别内型,用随机森林分类器在验证队列预测内型分配,并行差异基因表达、通路富集和数字细胞术分析。
  • 在发现队列中识别出两种内型USE-1和USE-2;USE-2以中性粒细胞驱动的固有免疫激活和淋巴细胞抑制为标志,与更高生理严重度和更高死亡率相关(41.3% vs 22.0%;绝对差19.3%,95%CI 7.6-30.9%),且不受HIV、结核或疟疾感染影响。
  • 13基因分类器(误分类率1.43%)在验证队列中复制出两种内型,生物学和临床特征相似。
  • USE-2与SRS1和炎症型内型有强转录重叠,但患者层面分配仅中度一致;与Mars1的重叠可变。

证据类型、等级与局限

  • 证据类型:两个前瞻性观察队列的推导与验证研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,乌干达脓毒症患者中识别的两种转录组内型反映了可靶向病理生物学的个体间差异,并在高负担感染中提供预后富集。
  • 作者结论认为,与高收入国家来源内型的差异凸显了需要兼具全球相关性和本地响应性的脓毒症分类。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Sub-Saharan Africa carries the highest global burden of critical illness, yet transcriptomic sepsis endotypes have not been defined in the region. Their clinical relevance and alignment with endotypes identified in high-income countries (HICs) remain unknown.

METHODS: We analyzed data from two prospective observational cohorts of critically ill adults with sepsis in Uganda (discovery cohort [Tororo, rural], N = 243; validation cohort [Entebbe, urban], N = 112). Unsupervised clustering of whole-blood RNAseq data was used to identify endotypes in the discovery cohort. A random forest classifier was used to predict endotype assignment in the validation cohort. Differential gene expression, pathway enrichment, and digital cytometry were used to define endotype pathobiology and determine overlap with HIC-derived endotypes.

RESULTS: Two endotypes-Uganda Sepsis Endotypes 1 (USE-1) and 2 (USE-2)-were identified in the discovery cohort. USE-2, marked by neutrophil-driven innate immune activation and lymphocyte suppression, was associated with greater physiological severity and higher mortality (41.3% vs. 22.0%; absolute difference 19.3%, 95% CI 7.6-30.9%), irrespective of HIV, tuberculosis, or malaria infection. A 13-gene classifier (misclassification rate 1.43%) replicated two endotypes in the validation cohort with similar biological and clinical profiles. USE-2 showed strong transcriptional overlap with SRS1 and inflammopathic endotypes but only modest concordance in patient-level assignments. Overlap with Mars1 was variable.

CONCLUSIONS: We identified two transcriptomic sepsis endotypes in Uganda that reflect inter-individual differences in targetable pathobiology and confer prognostic enrichment across high-burden infections. Divergence from HIC-derived endotypes highlights the need for sepsis classifications that are both globally relevant and locally responsive.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Cummings MJ, Lutwama JJ, Tomoiaga AS, et al. Identification of transcriptomic sepsis endotypes in sub-Saharan Africa: derivation, validation, and global alignment in two Ugandan cohorts. Intensive Care Med. 2025. PMID: 40728637. doi:10.1007/s00134-025-08047-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。